Komodo Health Acquires Breakaway Partners to Improve Patient Access to Effective Therapies
Tuesday, July 27, 2021
Komodo Health today announced the acquisition of Breakaway Partners, a leading market access software company for the life sciences industry. The acquisition brings together Komodo’s Healthcare Map™ and software with Breakaway Partners’ industry-leading formulary data, policy criteria, and analytics platform to create the industry’s first enterprise market access solution suite based on a comprehensive, real-time view of real-world outcomes and costs.
As healthcare payers and providers continue to shift to value-based payment models, which incentivize the use of the most effective therapies, the market access analytics field has become critical to determine restrictions, reimbursement levels, and coverage decisions. In a domain ripe for innovation, Breakaway Partners has emerged as the leader. Its software solutions track formulary changes, medical and pharmacy policy criteria, and payer coverage – in real time and across geographies – to inform market landscape strategies for new and existing therapies.
"Together, Komodo and Breakaway are pairing the largest map of real-world evidence with real-time market access insights," said Arif Nathoo, MD, CEO and co-founder of Komodo Health. “Breakaway is a pioneer in using technology to provide market access teams real-time insights on policy decisions. We couldn’t be more thrilled to add their solutions and expertise to further our mission of reducing the burden of disease.”
“Gaps in access lead to gaps in care delivery,” added Web Sun, President and co-founder of Komodo Health. “In a value-driven world, payers, providers and life sciences companies need faster, more complete insights to bridge the gap between new breakthroughs, the potential impact on patient outcomes, and formulary decisions. With this acquisition, we will be delivering solutions that encompass a real-time, comprehensive view of the entire market access landscape.”
Historically, market access decisions have been based on expensive, manual, and time-intensive analyses of aggregated formulary and policy criteria. The resulting insights were often out-of-date and incomplete, and they lacked visibility into patient outcomes. Now, through a single software interface, it will be possible to quickly understand and prioritize patient access with insights rooted in the current landscape of existing restrictions, as well as the real-world experience of individual patients.
“Legacy formulary aggregators not only lack the depth and breadth of data to see patient outcomes, but also the intuitive software to unlock the insights,” said Christian Pinsonault, Managing Partner at Breakaway Partners. “Together, we are making it possible to track the impact of policy and formulary decisions on patient outcomes and – more importantly – to inform value-driven strategies that improve those outcomes. It will now be possible to quickly understand and prioritize patient access based not only on the current landscape of existing policy restrictions, but also on the real-world experience of individual patients.”
Together, Komodo Health and Breakaway Partners will expand their software capabilities, powered by insights from Komodo's Healthcare Map, the industry’s largest and most complete database of de-identified, real-world patient data, which tracks more than 325 million de-identified patient journeys. The acquisition further extends Komodo Heath’s expansion across the healthcare ecosystem, delivering a range of real-world data, analytics, and software solutions designed to close gaps in care, improve access, and reduce the burden of disease.